Novartis AG (NVS) Shares Bought by Mawer Investment Management Ltd.
Mawer Investment Management Ltd. lifted its position in shares of Novartis AG (NYSE:NVS) by 3.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,758,166 shares of the company’s stock after buying an additional 92,908 shares during the quarter. Novartis makes up 1.9% of Mawer Investment Management Ltd.’s holdings, making the stock its 15th largest holding. Mawer Investment Management Ltd. owned about 0.12% of Novartis worth $231,576,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of NVS. Wealthcare Advisory Partners LLC bought a new stake in Novartis during the third quarter valued at about $106,000. Cable Hill Partners LLC raised its stake in Novartis by 588.8% in the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after buying an additional 1,107 shares during the last quarter. Calton & Associates Inc. purchased a new stake in Novartis in the fourth quarter valued at about $118,000. SeaCrest Wealth Management LLC purchased a new stake in Novartis in the fourth quarter valued at about $124,000. Finally, Trustcore Financial Services LLC purchased a new position in shares of Novartis in the fourth quarter worth about $178,000. 10.80% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently weighed in on NVS. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Thursday, January 18th. UBS Group reissued a “neutral” rating on shares of Novartis in a report on Monday, January 15th. Bank of America lowered Novartis from a “neutral” rating to an “underperform” rating in a research note on Wednesday, December 6th. Finally, Zacks Investment Research lowered Novartis from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the stock. Novartis presently has a consensus rating of “Hold” and an average target price of $85.32.
Novartis (NYSE:NVS) last released its earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.04. The firm had revenue of $12.92 billion during the quarter, compared to analysts’ expectations of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. Novartis’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.14 EPS. sell-side analysts expect that Novartis AG will post 5.36 EPS for the current fiscal year.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.